Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,963 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,963 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Open enrollment, early-phase tilt

Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.

423
recruiting participants now
34%
of trials open to enrollment
120
in Phase 3-4 (later-stage)
98
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Open and recent trials

1,251 total, page 20 of 26

COMPLETED NA 75 participants

Evaluation of Breast CT

University of California, Davis

NCT00584233

COMPLETED NA 75 participants

Nipple Sparing Mastectomy - Cosmetic Outcomes

Wake Forest University Health Sciences

NCT01002014

COMPLETED NA 75 participants

Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

Stanford University

NCT00383500

COMPLETED Phase 1 73 participants

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Pfizer

NCT04672460

COMPLETED NA 72 participants

Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors

Indiana University

NCT03712813

COMPLETED NA 72 participants

Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors

University of Vermont

NCT01482702

COMPLETED Phase 2 72 participants

Protocol for Women at Increased Risk of Developing Breast Cancer

Carol Fabian, MD

NCT00291694

COMPLETED Phase 3 72 participants

Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer

HealthPartners Institute

NCT00202059

COMPLETED Phase 2 72 participants

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Angiochem

NCT02048059

COMPLETED Phase 4 72 participants

Intra-operative Digital vs. Standard Mammography

Massachusetts General Hospital

NCT01766102

COMPLETED NA 72 participants

A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors

University of Utah

NCT04594473

COMPLETED Phase 1 71 participants

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Genentech

NCT00960960

COMPLETED Phase 2 70 participants

Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

Emory University

NCT00912340

COMPLETED Phase 4 70 participants

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

NCT00190697

COMPLETED Phase 2 70 participants

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

City of Hope Medical Center

NCT00002937

COMPLETED Phase 2 70 participants

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

GE Healthcare

NCT00918281

COMPLETED Phase 2 70 participants

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Nektar Therapeutics

NCT00802945

COMPLETED Phase 2 70 participants

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT01276041

COMPLETED Phase 2 69 participants

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

NYU Langone Health

NCT02280252

COMPLETED 68 participants

Nutrition, Physical Activity, and Cognition in Breast Cancer Survivors

Texas State University, San Marcos

NCT02591316

COMPLETED Phase 1 68 participants

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

Abramson Cancer Center at Penn Medicine

NCT04023110

COMPLETED 68 participants

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

Duke University

NCT03719495

COMPLETED 68 participants

Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer

University of Michigan Rogel Cancer Center

NCT00161265

COMPLETED Phase 2 68 participants

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

NCIC Clinical Trials Group

NCT00238316

COMPLETED NA 68 participants

Promoting a Healthier Lifestyle Among Breast Cancer Survivors

H. Lee Moffitt Cancer Center and Research Institute

NCT01419613

COMPLETED 67 participants

Development of a Clinical Trial Specific Question Prompt List

Memorial Sloan Kettering Cancer Center

NCT00662324

COMPLETED 66 participants

Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome

Weill Medical College of Cornell University

NCT03383107

COMPLETED Phase 2 65 participants

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Baylor Breast Care Center

NCT00548184

COMPLETED Phase 2 65 participants

Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer

Mayo Clinic

NCT01215162

COMPLETED Phase 1 64 participants

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Tvardi Therapeutics, Incorporated

NCT03195699

COMPLETED Phase 4 63 participants

Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer

Xoft

NCT00742222

COMPLETED NA 63 participants

Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy

Columbia University

NCT01163682

COMPLETED NA 62 participants

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

Massachusetts General Hospital

NCT02871115

COMPLETED Phase 1 62 participants

Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors

University of Illinois at Chicago

NCT05615753

COMPLETED 60 participants

Automated Pain Intervention for Underserved Minority Breast Cancer Patients

M.D. Anderson Cancer Center

NCT00881010

COMPLETED NA 60 participants

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

National Institutes of Health Clinical Center (CC)

NCT00080860

COMPLETED 60 participants

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

Carl Ade, M.S., Ph.D.

NCT03062878

COMPLETED NA 60 participants

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

Mayo Clinic

NCT00436917

COMPLETED Phase 1 60 participants

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

National Cancer Institute (NCI)

NCT00470301

COMPLETED NA 60 participants

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

New Mexico Cancer Research Alliance

NCT01821833

COMPLETED 59 participants

Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

Dana-Farber Cancer Institute

NCT00973440

COMPLETED Phase 2 59 participants

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

NCT00006007

COMPLETED Phase 1 58 participants

Vaccination of High Risk Breast Cancer Patients

University of Arkansas

NCT02229084

COMPLETED Phase 1 58 participants

DC Vaccine for Patients With Ductal Carcinoma In Situ

Abramson Cancer Center at Penn Medicine

NCT02061332

COMPLETED Phase 3 57 participants

Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer

M.D. Anderson Cancer Center

NCT00046865

COMPLETED NA 55 participants

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

Craig A. Bunnell, MD, MPH

NCT00146588

COMPLETED Phase 2 55 participants

Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

David Peereboom, MD

NCT00450866

COMPLETED Phase 2 55 participants

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

National Institutes of Health Clinical Center (CC)

NCT00019812

COMPLETED NA 54 participants

Treating Cancer-Related Fatigue Through Systematic Light Exposure

Icahn School of Medicine at Mount Sinai

NCT01873794

COMPLETED Phase 2 53 participants

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

NCT00410657

← Previous Page 20 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Breast Cancer right now

423 recruiting of 1,251 indexed (34% open).

Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Breast Cancer?

PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Breast Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.